Prof. Dr. Marcus Schittenhelm
Leitender Arzt
Ärztliche Leitung Ambulatorium Spital Linth
Medizinische Onkologie und Hämatologie · Dept. I
Cell-cycle progression and response of germ cell tumors to cisplatin in vitro
Mueller S, Schittenhelm M, Honecker F, Malenke E, Lauber K, Wesselborg S, Hartmann J, Bokemeyer C, Mayer F. Cell-cycle progression and response of germ cell tumors to cisplatin in vitro. Int J Oncol 2006; 29:471-9.
01.08.2006Cell-cycle progression and response of germ cell tumors to cisplatin in vitro
01.08.2006Int J Oncol 2006; 29:471-9
Mueller Sandra, Schittenhelm Marcus, Honecker Friedemann, Malenke Elke, Lauber Kirsten, Wesselborg Sebastian, Hartmann Joerg T, Bokemeyer Carsten, Mayer Frank
A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)
Kollmannsberger C, Schittenhelm M, Honecker F, Tillner J, Weber D, Oechsle K, Kanz L, Bokemeyer C. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2006; 17:1007-13.
13.03.2006A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)
13.03.2006Ann Oncol 2006; 17:1007-13
Kollmannsberger C, Schittenhelm Marcus, Honecker F, Tillner J, Weber D, Oechsle K, Kanz L, Bokemeyer C
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies
Schittenhelm M, Druker B, Deininger M, Bokemeyer C, Lee F, Griffith D, Corbin A, Schroeder A, Shiraga S, Heinrich M. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006; 66:473-81.
01.01.2006Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies
01.01.2006Cancer Res 2006; 66:473-81
Schittenhelm Marcus, Druker Brian J, Deininger Michael W N, Bokemeyer Carsten, Lee Francis Y, Griffith Diana, Corbin Amie S, Schroeder Arin, Shiraga Sharon, Heinrich Michael C
Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells
Yee K, Schittenhelm M, O'Farrell A, Town A, McGreevey L, Bainbridge T, Cherrington J, Heinrich M. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood 2004; 104:4202-9.
10.08.2004Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells
10.08.2004Blood 2004; 104:4202-9
Yee Kevin W H, Schittenhelm Marcus, O'Farrell Anne-Marie, Town Ajia R, McGreevey Laura, Bainbridge Troy, Cherrington Julie M, Heinrich Michael C
Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro
Koch S, Mayer F, Honecker F, Schittenhelm M, Bokemeyer C. Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro. Br J Cancer 2003; 89:2133-9.
01.12.2003Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro
01.12.2003Br J Cancer 2003; 89:2133-9
Koch S, Mayer F, Honecker F, Schittenhelm Marcus, Bokemeyer C
Complete remission of third recurrence of acute myeloid leukemia after treatment with imatinib (STI-571)
Schittenhelm M, Aichele O, Kröber S, Brümmendorf T, Kanz L, Denzlinger C. Complete remission of third recurrence of acute myeloid leukemia after treatment with imatinib (STI-571). Leuk Lymphoma 2003; 44:1251-3.
01.07.2003Complete remission of third recurrence of acute myeloid leukemia after treatment with imatinib (STI-571)
01.07.2003Leuk Lymphoma 2003; 44:1251-3
Schittenhelm Marcus, Aichele O, Kröber S M, Brümmendorf T, Kanz L, Denzlinger C
Enhanced erythrocyte apoptosis in sickle cell anemia, thalassemia and glucose-6-phosphate dehydrogenase deficiency
Lang K, Huber S, Lang F, Fritz J, Kanz L, Scheel-Walter H, Schittenhelm M, Myssina S, Roll B, Wieder T. Enhanced erythrocyte apoptosis in sickle cell anemia, thalassemia and glucose-6-phosphate dehydrogenase deficiency. Cell Physiol Biochem 2002; 12:365-72.
01.01.2002Enhanced erythrocyte apoptosis in sickle cell anemia, thalassemia and glucose-6-phosphate dehydrogenase deficiency
01.01.2002Cell Physiol Biochem 2002; 12:365-72
Lang Karl S, Huber Stephan M, Lang Florian, Fritz Jasmin, Kanz Lothar, Scheel-Walter Hans-Gerhard, Schittenhelm Marcus, Myssina Svetlana, Roll Benjamin, Wieder Thomas
Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia
Möhle R, Schittenhelm M, Failenschmid C, Bautz F, Kratz-Albers K, Serve H, Brugger W, Kanz L. Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia. Br J Haematol 2000; 110:563-72.
01.09.2000Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia
01.09.2000Br J Haematol 2000; 110:563-72
Möhle R, Schittenhelm Marcus, Failenschmid C, Bautz F, Kratz-Albers K, Serve H, Brugger W, Kanz L